Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

The Role of Serotonin in Seizures
Imaging Serotoninergic Neurotransmission in Epilepsy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Role of Serotonin in Seizures
Imaging Serotoninergic Neurotransmission in Epilepsy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia and Other Focal Dystonias
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia and Other Focal Dystonias
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Warfighter Head Injury Study
Warfighter Head Injury Study a Comprehensive, Multidisciplinary Research Evaluation
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Warfighter Head Injury Study
Warfighter Head Injury Study a Comprehensive, Multidisciplinary Research Evaluation
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation
Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation
Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Identification of Characteristics Associated With Symptom Remission in Autism
Characterization of Autism Spectrum Disorder in School Aged Children
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Identification of Characteristics Associated With Symptom Remission in Autism
Characterization of Autism Spectrum Disorder in School Aged Children
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cholesterol in ASD: Characterization and Treatment
Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cholesterol in ASD: Characterization and Treatment
Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury
Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury
Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy
Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy
Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Status: Enrolling
Updated:  10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Status: Enrolling
Updated: 10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans
The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans
The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain P-gp and Inflammation in People With Epilepsy
Positron Emission Tomography Measurement of Neuroinflammation in Focal Epilepsy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Brain P-gp and Inflammation in People With Epilepsy
Positron Emission Tomography Measurement of Neuroinflammation in Focal Epilepsy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Yale University School of Medicine
mi
from
New Haven, CT
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Sudarshan K. Sharma, Md
mi
from
Hinsdale, IL
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Sudarshan K. Sharma, Md
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Women's Cancer Care
mi
from
Covington, LA
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Women's Cancer Care
mi
from
Covington, LA
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Winship Cancer Institute
mi
from
Atlanta, GA
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Augusta University
mi
from
Augusta, GA
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Dana Faber Cancer Institute
mi
from
Boston, MA
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
The Charlotte-Mecklenburg Hospital Authority
mi
from
Charlotte, NC
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
The Charlotte-Mecklenburg Hospital Authority
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Oklahoma Cancer Specialists and Research Institute, LLC
mi
from
Tulsa, OK
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Oklahoma Cancer Specialists and Research Institute, LLC
mi
from
Tulsa, OK
Click here to add this to my saved trials
Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation
Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)
Status: Enrolling
Updated:  10/5/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation
Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)
Status: Enrolling
Updated: 10/5/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Measuring Levels of SMN in Blood Samples of SMA Patients
SMN Levels in Peripheral Blood Samples of SMA Patients and the Effects of Pharmacological Compounds In Vitro
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Measuring Levels of SMN in Blood Samples of SMA Patients
SMN Levels in Peripheral Blood Samples of SMA Patients and the Effects of Pharmacological Compounds In Vitro
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Status: Enrolling
Updated:  10/5/2017
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Status: Enrolling
Updated: 10/5/2017
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
MC-5A for Chemotherapy Induced Peripheral Neuropathy
Treatment of Painful Chemotherapy -Induced Peripheral Neuropathy With the MC-5A Pain Therapy Medical Device, a Randomized, Double-Blind, Sham-Controlled Clinical Trial
Status: Enrolling
Updated:  10/6/2017
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
MC-5A for Chemotherapy Induced Peripheral Neuropathy
Treatment of Painful Chemotherapy -Induced Peripheral Neuropathy With the MC-5A Pain Therapy Medical Device, a Randomized, Double-Blind, Sham-Controlled Clinical Trial
Status: Enrolling
Updated: 10/6/2017
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Quantification of Balance in Acutely Concussed Athletes
Quantification of Balance in Acutely Concussed Athletes, Implications for Return to Play Determination
Status: Enrolling
Updated:  10/6/2017
Oregon Health and Science University
mi
from
Portland, OR
Quantification of Balance in Acutely Concussed Athletes
Quantification of Balance in Acutely Concussed Athletes, Implications for Return to Play Determination
Status: Enrolling
Updated: 10/6/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Charleston, SC
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Anaheim, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Carson, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Carson, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Colton, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Colton, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Costa Mesa, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Downey, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Glendale, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
National City, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Oceanside, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Paramount, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Paramount, CA
Click here to add this to my saved trials